

IN THE TITLE

Replace the title by:

**--ISOLATED NUCLEIC ACID MOLECULES WHICH
ENCODE PEPTIDES WHICH BIND TO MHC CLASS
II MOLECULES, SUCH AS HLA-DR53--**

IN THE SPECIFICATION

Applicants are attaching replacement pages to indicate the following amendments.

Page 1, lines 1-7, please replace with the following:

--RELATED APPLICATIONS

This application is a divisional of Serial Number 09/165,546, filed on October 2, 1998, which is a continuation-in-part of Serial Number 09/062,422, filed on April 17, 1998, now U.S. Patent Number 6,252,052, which is a continuation-in-part of Serial Number 08/937,263, filed on September 15, 1997, now U.S. Patent Number 6,274,145, which is a continuation-in-part of Serial Number 08/725,182, filed on October 3, 1996, now U.S. Patent No. 5,804,381. All patents are incorporated by reference.--

Page 6, lines 4-5, please replace by:

--Figure 3 shows potential sites for modification of the deduced amino acid sequence of NY-ESO-1 (the amino acid sequence is encoded by the nucleotide sequence of SEQ ID NO: 1, and is set forth therein).--

Page 28, lines 2-4, please replace by:

--Further studies were carried out to determine if CD4⁺ helper T cells recognized complexes of MHC Class II molecules and peptides.--

Page 28, lines 5-10, please replace by:

--Tumor cell line MZ-MEL-19 has been types as being HLA-DR53 positive. Hence, NY-ESO-1 was screened using Futaki, et al., *Immunogenetics*, 42:299-301 (1995), incorporated by reference, which teaches binding motifs for HLA-DR53. A total of twenty-eight peptides which, in theory, would bind to HLA-DR53 were found.--